Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for 688393.SS and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for 688393.SS and 80,000+ other tickers.
See exactly how 688393.SS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 688393.SS and 80,000+ other tickers.
Guangzhou LBP Medicine Science & Technology Co., Ltd. specializes in the development and manufacture of innovative pathological diagnostic solutions for the Chinese market. Its comprehensive product portfolio includes advanced pathological diagnostic reagents and essential ancillary equipment. Among these are liquid-based cytology (LBC) offerings, encompassing both gynecological and non-gynecological series, complemented by specialized equipment. The company also provides fluorescence in situ hybridization (FISH) products, which are applied across a broad spectrum of conditions. These…
No recent news available.